A review of finger-worn devices reported 87% pooled accuracy for sleep–wake classification against PSG (95% confidence interval: 86%–89%). That means roughly 87 of every 100 assessed time segments were labeled correctly across the pooled studies. The interval describes uncertainty around the pooled estimate, not the spread of individual nightly errors. Participants in the sleep-staging studies were mainly healthy. This result does not mean every ring detects 87% of awakenings. Overall accuracy combines two tasks: recognizing sleep and recognizing wake. Strong performance on one can conceal weakness on the other.

A small study of the older Basis B1 wearable illustrates the difference. In 18 healthy adults monitored over consecutive nights, with 40 nights analyzed, it recognized about 99% of sleep segments but only 8% of wake segments. It significantly overestimated

A review of six Oura studies in generally healthy participants compared the ring with PSG or actigraphy, a movement-based estimate of sleep. It found no statistically significant average differences in total sleep time or reported sleep-stage durations. The pooled total-sleep mean difference was −2.97 minutes (95% confidence interval: −10.27 to 4.33 minutes), meaning the ring recorded about three minutes less sleep on average. Other pooled mean differences were −1.32 percentage points for sleep efficiency (95% CI: −2.76 to 0.12), +1.64 minutes for wake after sleep onset (95% CI: −12.57 to 15.86), and −4.27 minutes for light sleep (95% CI: −24.68 to 16.13). These intervals describe uncertainty around the pooled means, not the spread of individual nightly errors. That is encouraging for agreement in group averages, but it is not a three-minute accuracy guarantee for your next night.

Overestimates and underestimates can cancel when averaged. Small average differences therefore do not prove that two methods are interchangeable for an individual. A tracker can also assign stages to the wrong parts of the night yet produce similar total minutes in each stage.

A study of 11 trackers tested 75 adults with sleep complaints at two Korean clinical centers. Stage agreement with PSG varied widely across watches, a ring, bedside sensors, and phone apps. Macro F1 scores, which summarize classification performance across stages on a 0–1 scale, ranged from 0.26 to 0.69; higher scores are better. These scores are not directly comparable with the finger-device review's accuracy percentages. Devices that performed better for deep sleep were not necessarily strongest for rapid eye movement, or REM, sleep. REM is a sleep stage often associated with vivid dreams. One device's validation results are not proof for another model or software version.

The errors were not always fixed, either. Wearable estimates of sleep efficiency—the share of time in bed spent asleep—showed errors that changed with the true value. Bedside devices showed similar problems estimating time taken to fall asleep. Performance also differed across groups

Matching PSG on sleep duration does not establish that a device can diagnose insomnia or rule out sleep apnea. Obstructive sleep apnea involves repeated narrowing or closure of the airway during sleep. The finger-device review found better screening performance for severe apnea than mild disease. Those apnea studies involved clinical populations, unlike the mainly healthy groups used for sleep staging. Some tested devices show promise for flagging severe cases, but that finding does not validate every consumer ring.

The American Academy of Sleep Medicine's 2018 statement says technologies intended for diagnosis or treatment need rigorous testing and FDA clearance. It also emphasizes that consumer sleep data should not replace a clinical evaluation. A practical safety concern is

A review of finger-worn devices reported 87% pooled accuracy for sleep–wake classification against PSG (95% confidence interval: 86%–89%). That means roughly 87 of every 100 assessed time segments were labeled correctly across the pooled studies. The interval describes uncertainty around the pooled estimate, not the spread of individual nightly errors. Participants in the sleep-staging studies were mainly healthy. This result does not mean every ring detects 87% of awakenings. Overall accuracy combines two tasks: recognizing sleep and recognizing wake. Strong performance on one can conceal weakness on the other.

A small study of the older Basis B1 wearable illustrates the difference. In 18 healthy adults monitored over consecutive nights, with 40 nights analyzed, it recognized about 99% of sleep segments but only 8% of wake segments. It significantly overestimated

A review of six Oura studies in generally healthy participants compared the ring with PSG or actigraphy, a movement-based estimate of sleep. It found no statistically significant average differences in total sleep time or reported sleep-stage durations. The pooled total-sleep mean difference was −2.97 minutes (95% confidence interval: −10.27 to 4.33 minutes), meaning the ring recorded about three minutes less sleep on average. Other pooled mean differences were −1.32 percentage points for sleep efficiency (95% CI: −2.76 to 0.12), +1.64 minutes for wake after sleep onset (95% CI: −12.57 to 15.86), and −4.27 minutes for light sleep (95% CI: −24.68 to 16.13). These intervals describe uncertainty around the pooled means, not the spread of individual nightly errors. That is encouraging for agreement in group averages, but it is not a three-minute accuracy guarantee for your next night.

Overestimates and underestimates can cancel when averaged. Small average differences therefore do not prove that two methods are interchangeable for an individual. A tracker can also assign stages to the wrong parts of the night yet produce similar total minutes in each stage.

A study of 11 trackers tested 75 adults with sleep complaints at two Korean clinical centers. Stage agreement with PSG varied widely across watches, a ring, bedside sensors, and phone apps. Macro F1 scores, which summarize classification performance across stages on a 0–1 scale, ranged from 0.26 to 0.69; higher scores are better. These scores are not directly comparable with the finger-device review's accuracy percentages. Devices that performed better for deep sleep were not necessarily strongest for rapid eye movement, or REM, sleep. REM is a sleep stage often associated with vivid dreams. One device's validation results are not proof for another model or software version.

The errors were not always fixed, either. Wearable estimates of sleep efficiency—the share of time in bed spent asleep—showed errors that changed with the true value. Bedside devices showed similar problems estimating time taken to fall asleep. Performance also differed across groups

Matching PSG on sleep duration does not establish that a device can diagnose insomnia or rule out sleep apnea. Obstructive sleep apnea involves repeated narrowing or closure of the airway during sleep. The finger-device review found better screening performance for severe apnea than mild disease. Those apnea studies involved clinical populations, unlike the mainly healthy groups used for sleep staging. Some tested devices show promise for flagging severe cases, but that finding does not validate every consumer ring.

The American Academy of Sleep Medicine's 2018 statement says technologies intended for diagnosis or treatment need rigorous testing and FDA clearance. It also emphasizes that consumer sleep data should not replace a clinical evaluation. A practical safety concern is